文献速递前列腺癌

不可逆电穿孔治疗前列腺癌索引病灶的局灶治疗:中位随访3年的前瞻性研究

Focal Therapy of Prostate Cancer Index Lesion With Irreversible Electroporation. A Prospective Study With a Median Follow-up of 3 Years.
PubMed 文献 · J Urol · 2022-09-08

这项单中心II期研究纳入41例局限期前列腺癌患者,以不可逆电穿孔消融索引病灶,中位随访36个月。全队列39%出现复发,场内复发15%,场外复发33.3%,中位无复发生存32个月;63.4%免于挽救治疗,全部患者保留尿控,91.8%维持勃起功能。

要点

  • 41例患者中位随访36个月,全队列复发率39%,活检者中复发率48.4%。
  • 场内复发5例(15%),场外复发11例(33.3%),中位无复发生存32个月。
  • 63.4%免于挽救治疗,全部保留尿控,91.8%维持勃起功能。

核心结论

  • 在经选择的患者中,不可逆电穿孔可获得满意的3年场内肿瘤控制,且生活质量结果优异。

研究设计与样本

  • 单中心II期研究,纳入41例连续患者,中位随访36个月。

主要发现

  • 全队列41例中16例(39%)复发,接受活检的33例中16例(48.4%)复发。
  • 场内复发5例(15%),场外复发11例(33.3%)。
  • 41例中10例(24.6%)存在显著肿瘤,场内复发5例中3例(60%)存在显著肿瘤。
  • 中位无复发生存期为32个月(95%CI 6.7-57.2)。
  • 26例(63.4%)免于挽救治疗;全部患者保留尿控;91.8%维持勃起功能。

关键数值与推荐

  • 纳入标准:国际泌尿病理学会分级1-2级,前列腺特异性抗原≤15 ng/ml,≤cT2b。
  • 基于多参数磁共振成像及经会阴系统与靶向磁共振-超声融合引导活检筛选患者。
  • 主要终点为癌症控制,定义为无任何活检证实的肿瘤。
  • 计划在12个月时进行对照经会阴活检,并根据前列腺特异性抗原和/或多参数磁共振成像信息怀疑时活检。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our aim was to assess oncologic, safety, and quality of life-related outcomes of focal therapy with irreversible electroporation in men with localized prostate cancer. MATERIALS AND METHODS: This was a single-center, phase II study. INCLUSION CRITERIA: prostate cancer International Society of Urological Pathology grade 1-2, prostate specific antigen ≤15 ng/ml, ≤cT2b. Patients were selected based on multiparametric magnetic resonance imaging and transperineal systematic and targeted magnetic resonance imaging-ultrasound fusion-guided biopsy. Ablation of index lesions with safety margin was performed. Primary end point was cancer control, defined as the absence of any biopsy-proven tumor. A control transperineal biopsy was planned at 12 months and when suspected based on prostate specific antigen and/or multiparametric magnetic resonance imaging information. Quality of life was assessed using Expanded Prostate Cancer Index Composite Urinary Continence domain, International Index of Erectile Function, and International Prostate Symptom Score. RESULTS: From November 2014 to July 2021, 41 consecutive patients were included with a median follow-up of 36 months. Thirty patients (73%) had International Society of Urological Pathology grade 1 tumors, 10 (24%) grade 2, and 1 (2.4%) grade 3. Recurrence was observed in 16 of 41 (39%) of the whole cohort, and 16 of 33 (48.4%) who underwent biopsy. In-field recurrence was detected in 5 (15%) and out-of-field in 11 (33.3%). Ten of 41 (24.6%) including 3 of 5 (60%) with in-field recurrences had significant tumors (Gleason pattern 4-5; more than 1 core or any >5 mm involved). Median recurrence-free survival was 32 months (95% CI 6.7-57.2). Twenty-six patients (63.4%) were free from salvage treatment. All patients preserved urinary continence. Potency was maintained in 91.8%. CONCLUSIONS: Irreversible electroporation can achieve satisfactory 3-year in-field tumor control with excellent quality of life results in selected patients.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Miñana López B, Andrés Boville G, Barbas Bernardos G, et al. Focal Therapy of Prostate Cancer Index Lesion With Irreversible Electroporation. A Prospective Study With a Median Follow-up of 3 Years. J Urol. 2022. PMID: 36073928. doi:10.1097/JU.0000000000002970

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。